ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Discovery Laboratories, Inc." (DSCO) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Discovery Laboratories, Inc." (DSCO)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: LJPC, ANAC, CBPO, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Discovery Laboratories, Inc."© quotemedia

Company Profile

Discovery Laboratories, Inc., a biotechnology company, focuses on developing products for the treatment of respiratory disease. The company’s product pipeline includes Surfaxin, a synthetic, peptide-containing surfactant that has completed Phase-III pivotal trial for the prevention of respiratory distress syndrome (RDS) in premature infants; Surfaxin LS, a lyophilized dosage form of Surfaxin in Phase-III clinical trials, which enhances ease of use for healthcare practitioners; and AEROSURF, a drug-device combination product that has completed first pilot Phase II clinical study of aerosolized KL4 surfactant for the prevention of RDS in premature infants. It has license agreements with Philip Morris USA Inc.; Philip Morris Products S.A.; Johnson & Johnson; and Ortho Pharmaceutical Corporation for its capillary aerosolization and KL4 surfactant technologies. The company also has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Recent News: "Discovery Laboratories, Inc."